Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
12
GPCR Quote, Financials, Valuation and Earnings
Last price:
$28.25
Seasonality move
:
-41.18%
Day range:
$27.89 - $28.89
52-week range:
$26.23 - $62.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.80x
Volume:
247.5K
Avg. volume:
977.7K
1-year change:
-20.62%
Market cap:
$1.6B
Revenue:
--
EPS (TTM):
-$2.19
Analysts' Opinion
-
Consensus RatingStructure Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $85.75, Structure Therapeutics has an estimated upside of 203.54% from its current price of $28.25.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $65.00 representing 100% downside risk from its current price of $28.25.
Fair Value
-
According to the consensus of 6 analysts, Structure Therapeutics has 203.54% upside to fair value with a price target of $85.75 per share.
GPCR vs. S&P 500
-
Over the past 5 trading days, Structure Therapeutics has underperformed the S&P 500 by -12.83% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Structure Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Structure Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Structure Therapeutics reported revenues of --.
Earnings Growth
-
Structure Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Structure Therapeutics reported earnings per share of -$0.60.
Enterprise value:
702.3M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-6.73x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$52.9M | -$84.7M | -$142.2M | -$26.1M | -$45.8M | |
| EBITDA | -$52.6M | -$84.4M | -$141.4M | -$26.1M | -$45.6M | |
| Diluted EPS | -$2.21 | -$2.29 | -$2.19 | -$0.63 | -$0.60 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $104.8M | $210M | $923.7M | |
| Total Assets | -- | -- | $108.4M | $216.4M | $933.2M | |
| Current Liabilities | -- | -- | $12.2M | $20.1M | $33.4M | |
| Total Liabilities | -- | -- | $212.3M | $23.4M | $36.4M | |
| Total Equity | -- | -- | -$103.9M | $193M | $896.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$69.8M | -$101.9M | -$20.6M | -$19.7M | |
| Cash From Investing | -- | -$77.3M | -$572.9M | $30.1M | -$189M | |
| Cash From Financing | -- | $169.6M | $796.3M | $473K | -$757K | |
| Free Cash Flow | -- | -$70.9M | -$104.3M | -$21.4M | -$20.4M | |
GPCR
Sector
Market Cap
$1.6B
$46.1M
Price % of 52-Week High
45.03%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-20.62%
-30.52%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$29.54
200-day SMA
Sell
Level
$38.64
Bollinger Bands (100)
Sell
Level
33.21 - 40.79
Chaikin Money Flow
Sell
Level
-17.2M
20-day SMA
Sell
Level
$31.88
Relative Strength Index (RSI14)
Sell
Level
37.23
ADX Line
Buy
Level
25.65
Williams %R
Buy
Level
-80.185
50-day SMA
Sell
Level
$35.05
MACD (12, 26)
Sell
Level
-1.85
25-day Aroon Oscillator
Sell
Level
-28
On Balance Volume
Neutral
Level
7.4M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
Stock Forecast FAQ
In the current month, GPCR has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GPCR average analyst price target in the past 3 months is $85.75.
-
Where Will Structure Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Structure Therapeutics share price will rise to $85.75 per share over the next 12 months.
-
What Do Analysts Say About Structure Therapeutics?
Analysts are divided on their view about Structure Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Structure Therapeutics is a Sell and believe this share price will drop from its current level to $65.00.
-
What Is Structure Therapeutics's Price Target?
The price target for Structure Therapeutics over the next 1-year time period is forecast to be $85.75 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GPCR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Structure Therapeutics is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GPCR?
You can purchase shares of Structure Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Structure Therapeutics shares.
-
What Is The Structure Therapeutics Share Price Today?
Structure Therapeutics was last trading at $28.25 per share. This represents the most recent stock quote for Structure Therapeutics. Yesterday, Structure Therapeutics closed at $28.25 per share.
-
How To Buy Structure Therapeutics Stock Online?
In order to purchase Structure Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 26
Power Solutions International [PSIX] is down 16.62% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 2.25% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 1.67% over the past day.
